Barclays’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-531,203
| Closed | -$38.3M | – | 5370 |
|
|
2025
Q4 | $38.3M | Buy |
531,203
+178,916
| +51% | +$11.6M | 0.01% | 908 |
|
|
2025
Q3 | $15.3M | Sell |
352,287
-19,483
| -5% | -$788K | ﹤0.01% | 1376 |
|
|
2025
Q2 | $10.6M | Buy |
371,770
+47,875
| +15% | +$1.43M | ﹤0.01% | 1542 |
|
|
2025
Q1 | $9.56M | Buy |
323,895
+73,884
| +30% | +$2.3M | ﹤0.01% | 1442 |
|
|
2024
Q4 | $7.27M | Sell |
250,011
-5,688
| -2% | -$238K | ﹤0.01% | 1828 |
|
|
2024
Q3 | $11.7M | Buy |
255,699
+163,905
| +179% | +$7.11M | ﹤0.01% | 1364 |
|
|
2024
Q2 | $3.75M | Sell |
91,794
-32,152
| -26% | -$923K | ﹤0.01% | 1715 |
|
|
2024
Q1 | $3.16M | Sell |
123,946
-74,168
| -37% | -$1.16M | ﹤0.01% | 2178 |
|
|
2023
Q4 | $1.79M | Buy |
198,114
+8,794
| +5% | +$58.8K | ﹤0.01% | 2999 |
|
|
2023
Q3 | $1.21M | Sell |
189,320
-314,350
| -62% | -$2.71M | ﹤0.01% | 2193 |
|
|
2023
Q2 | $5.59M | Buy |
503,670
+132,047
| +36% | +$1.66M | ﹤0.01% | 1286 |
|
|
2023
Q1 | $5.7M | Sell |
371,623
-4,857
| -1% | -$107K | ﹤0.01% | 1455 |
|
|
2022
Q4 | $8.35M | Buy |
376,480
+206,715
| +122% | +$3.08M | ﹤0.01% | 1300 |
|
|
2022
Q3 | $2.77M | Buy |
169,765
+39,730
| +31% | +$760K | ﹤0.01% | 1520 |
|
|
2022
Q2 | $1.89M | Buy |
130,035
+78,709
| +153% | +$1.17M | ﹤0.01% | 1891 |
|
|
2022
Q1 | $947K | Buy |
+51,326
| New | +$872K | ﹤0.01% | 2457 |
|
Other funds holding RNAM
Barclays's RNAM Position: Q1 2026 in Review
Barclays sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 531,203 shares — an estimated $38.3M sold.
Barclays first reported a position in RNAM in Q1 2022 and held it in 16 quarters. The position peaked at $38.3M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Barclays reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Barclays sold 531,203 Avidity Biosciences shares in Q1 2026, an estimated $38.3M.
- Barclays first reported a position in Avidity Biosciences in Q1 2022 and held it in 16 quarters.
- Barclays's Avidity Biosciences position peaked at $38.3M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.